Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
391.4000 -5.90 (-1.49%)
NSE Jul 31, 2025 15:31 PM
Volume: 2.9M
 

logo
Biocon Ltd.
13 Aug 2023
391.40
-1.49%
ICICI Securities Limited
Biocon’s Q1FY24 performance was dragged by the biologics biz. Profitability of the segment was under pressure owing higher rebates in Fulphila (USD 15mn). Segmental PBT dropped 600bps QoQ to 1.6% in Q1FY24. US market share of Fulphila and Ogivri expanded by 200bps and 100bps QoQ to 16% and 11%, and stable at 12% for bGlargine.
Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.
More from Biocon Ltd.
Recommended